Brent Pfeiffenberger, the President and CEO of Century Therapeutics, Inc., has reported a transaction involving the sale of 31,172 shares of common stock. This transaction, which took place on November 13, 2026, is significant as it reflects the company's ongoing management of executive stock holdings and compliance with tax obligations.

According to the recent SEC filing, the shares were sold at a price of $1.65 per share. Following this transaction, Pfeiffenberger retains ownership of 3,602,667 shares of the company. The filing noted that the shares were withheld by the issuer to satisfy tax withholding obligations related to the vesting of restricted stock units.

Background

Century Therapeutics, Inc., identified under the Central Index Key (CIK) 0001850119, operates within the biological products sector, specifically focusing on biological products that do not include diagnostic substances. The company is incorporated in Delaware and has its business address in Philadelphia, Pennsylvania. Century Therapeutics is classified under the SIC code 2836.

What the Filing Says

The SEC filing, accession number 0002001162-26-000020, details the transaction as part of the company's compliance with SEC regulations. It specifies that the reporting owner, Brent Pfeiffenberger, is both a director and an officer of the company. The filing states, "Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units." This indicates a structured approach to managing executive compensation and tax liabilities.

Impact

This transaction may affect various stakeholders, including shareholders and potential investors, as it highlights the company's executive management practices. The biological products industry, which includes competitors such as other firms in the life sciences sector, may also observe how Century Therapeutics navigates executive stock management and compensation practices.

What's Next

The filing does not say what happens next.